PPIDT00116
Drug Information
| Name | Terlipressin |
|---|---|
| Sequence | GGGCYFQNCPKG |
| DrugBank_ID | DB02638 |
| Type | biotech |
| Indication | Terlipressin is a vasopressin receptor agonist indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. The US prescribing information states that patients with a serum creatinine > 5 mg/dL are unlikely to experience benefit from terlipressin.[L43217] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Solution | Intravenous |
0.85 mg
|
| Injection, powder, lyophilized, for solution | Intravenous |
1 mg
|
| Injection, powder, for solution | Parenteral |
1 MG/5ML
|
| Solution | Intravenous |
500 ug
|
| Solution | Intravenous |
1.000 mg
|
| Injection, powder, lyophilized, for solution | Intravenous |
0.86 mg
|
| Injection | Intravenous |
1 mg
|
| Injection, powder, for solution | Intravenous |
1 mg/8.5mL
|
| Injection, powder, for solution | Intravenous |
1 mg
|
| Injection, solution | Intravenous |
1 mg/8.5ml
|
| Solution | Parenteral |
0.850 mg
|
| Injection, powder, for solution | Parenteral |
1 mg
|
| Solution | Intravenous |
100000 mg
|
| Solution | Intravenous |
1.00 mg
|
| Solution | Parenteral |
1.000 mg
|
| Solution | — |
1 mg/8.5mL
|
| Injection, powder, for solution | — |
0.86 mg
|
| Injection, solution | Parenteral |
0.2 MG/ML
|
| Injection, solution | Parenteral |
1 MG/8.5ML
|
| Injection, solution | Parenteral |
0.1 MG/ML
|
| Injection, powder, lyophilized, for solution | Intravenous |
0.85 mg/5mL
|
| Powder | — |
1 mg/1vial
|
| Injection, solution | — |
1 mg/8.5ml
|
Target Information